Micromet News
Most Popular Micromet Story
UPDATED: Amgen scoops up Micromet tumor-fighting pipeline for $1.2B
Not to be left out of the M&A rush, Amgen said this morning that it will buy German/U.S. cancer drug developer Micromet ($MITI) for $1.16 billion in cash. At $11 a share, the deal gives its Read more...
Latest Headlines
- July 11, 2011
- June 10, 2011
- November 6, 2009
- October 29, 2009
- October 5, 2009
- October 3, 2008
- August 15, 2008
- March 15, 2007
- January 9, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
